Meeting
2023 ASCO Genitourinary Cancers Symposium
Survival outcomes of metastasis-directed therapy for solitary sites of metastatic clear cell renal cell carcinoma.
Authors
Akeem Ronell Lewis
Mayo Clinic, Rochester, MN
Akeem Ronell Lewis , Christine M. Lohse , Timothy D. Lyon , John Cheville , Bradley C. Leibovich , Vidit Sharma , Brian Addis Costello
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 674)
DOI
10.1200/JCO.2023.41.6_suppl.674
Abstract #
674
Poster Bd #
H6
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Time to next systemic therapy after stereotactic body radiation therapy for oligoprogressive metastatic castrate-resistant prostate cancer.
First Author: Corbin J. Eule
Poster
2023 ASCO Genitourinary Cancers Symposium
Multicenter population-level analysis of systemic therapy use in metastatic or recurrent prostate cancer.
First Author: Heba Mohamed
Poster
2023 ASCO Genitourinary Cancers Symposium
Overall survival, efficacy, and safety outcomes beyond front-line modern therapies in metastatic clear-cell renal cell carcinoma.
First Author: Jordyn Kreutzfeldt
Poster
2023 ASCO Genitourinary Cancers Symposium
The survival benefit of metastasectomy for metastatic non-clear cell renal cell carcinoma.
First Author: Jindong Dai